Suda Pharmaceuticals Ltd (SUD:ASX)
SUDA Pharmaceuticals Limited is a biotechnology company focused on developing therapies to treat human disease. The Company is focused on two areas which include oncology and conditions that impact the central nervous system. The Company is developing its invariant natural killer T (iNKT) cell therapy platform to treat blood cancers. The Company’s OroMist technology develop oral sprays to reformulate pharmaceuticals. Its ZolpiMist oral spray formulation of zolpidem tartrate to treat short-term insomnia. It is also developing oral sprays to treat migraine headaches, motion sickness, and drug-resistant epilepsy.